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Abstract
Background: Tissue injury elicits both hypersensitivity to evoked stimuli and ongoing, stimulus-independent pain.
We previously demonstrated that pain relief elicits reward in nerve-injured rats. This approach was used to evaluate
the temporal and mechanistic features of inflammation-induced ongoing pain.
Results: Intraplantar Complete Freund’s Adjuvant (CFA) produced thermal hyperalgesia and guarding behavior that
was reliably observed within 24 hrs and maintained, albeit diminished, 4 days post-administration. Spinal clonidine
produced robust conditioned place preference (CPP) in CFA treated rats 1 day, but not 4 days following CFA
administration. However, spinal clonidine blocked CFA-induced thermal hyperalgesia at both post-CFA days 1 and
4, indicating different time-courses of ongoing and evoked pain. Peripheral nerve block by lidocaine administration
into the popliteal fossa 1 day following intraplantar CFA produced a robust preference for the lidocaine paired
chamber, indicating that injury-induced ongoing pain is driven by afferent fibers innervating the site of injury.
Pretreatment with resiniferatoxin (RTX), an ultrapotent capsaicin analogue known to produce long-lasting
desensitization of TRPV1 positive afferents, fully blocked CFA-induced thermal hypersensitivity and abolished the
CPP elicited by administration of popliteal fossa lidocaine 24 hrs post-CFA. In addition, RTX pretreatment blocked
guarding behavior observed 1 day following intraplantar CFA. In contrast, administration of the selective TRPV1
receptor antagonist, AMG9810, at a dose that reversed CFA-induced thermal hyperalgesia failed to reduce
CFA-induced ongoing pain or guarding behavior.
Conclusions: These data demonstrate that inflammation induces both ongoing pain and evoked hypersensitivity
that can be differentiated on the basis of time course. Ongoing pain (a) is transient, (b) driven by peripheral input
resulting from the injury, (c) dependent on TRPV1 positive fibers and (d) not blocked by TRPV1 receptor
antagonism. Mechanisms underlying excitation of these afferent fibers in the early post-injury period will offer
insights for development of novel pain relieving strategies in the early post-traumatic period.
Background
Tissue injury elicited by trauma or disease produces
pain that is often described as dull, aching, throbbing
and ongoing. Additionally, injury produces long-lasting
tenderness at and surrounding the injury site that is
reflected by pain resulting from hypersensitivity to
external stimuli such as touch or movement. While
mechanisms underlying hypersensitivity to evoked sti-
muli have been extensively studied preclinically, under-
standing ongoing (i.e., non-evoked) pain in animal
models has been more difficult.
Ongoing pain, i.e., pain that is not “evoked” is an
important part the human pain experience, particularly
in the early periods following tissue damage such as
might occur in the post-operative state. Clinical and
preclinical reports indicate that such pain could be
mechanistically distinct from processes mediating
evoked hyperalgesia and/or allodynia [1-3]. Until
recently, limitations in approaches for measurement of
spontaneous or ongoing pain in animal models have
prevented detailed mechanistic explorations of such pain
[1,4,5]. We have recently shown that relief of experi-
mental neuropathic pain produces negative reinforce-
ment, demonstrated by place preference for a chamber
paired with pain relief, unmasking spontaneous pain [1].
Here, we determined whether this measure could be
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pain and to determine possible mechanisms underlying
acute injury-induced pain.
Several models for injury-induced pain have been
developed including hindpaw injection of complete
Freund’s adjuvant (CFA), a widely used model of persis-
tent inflammatory pain [6-9]. CFA produces thermal
and mechanical hypersensitivity lasting for several weeks
following administration into the hindpaw [7-9]. Addi-
tionally, CFA elicits time-dependent spontaneous activ-
ity of primary afferent fibers [6,10] that may underlie
injury-induced pain [6,10-13]. The mechanisms underly-
ing ongoing, unprovoked pain, as might correspond
clinically to pain at rest, are not well understood [5,13].
Here, we characterize the time-dependent expression of
injury-induced pain following hindpaw CFA-induced
inflammation, comparing measures of evoked pain,
guarding behavior, and conditioned place preference to
pain relief. Further, we begin to delineate specific affer-
ent subtypes that may drive CFA-induced pain.
Results
Injury-induced evoked and ongoing pain
Consistent with previous studies, CFA produced thermal
hypersensitivity within 24 hrs that lasted through 4 days
post injection, with an apparent time-dependent
decrease in injury-induced thermal hypersensitivity (Fig-
ure 1a, *p < 0.05 vs. BL,
#p < 0.05 vs. D1). Comparison
of difference scores confirms that there is a significant
decrease in the CFA-induced thermal hypersensitivity
across days. CFA induced a 10.6 ± 0.7 s change from BL
at D1 that decreased to a 5.2 ± 0.96 s change from BL
at D4 (p < 0.01, paired t-test).
CFA induced guarding behavior within 24 hours that
is diminished by 4 days post-injury (Figure 1b, ***p <
0.01 vs. BL; *p < 0.05 vs. BL). These findings are consis-
tent with the time-course of guarding behavior reported
with CFA [6].
In initial experiments, CFA-treated rats received spinal
saline both in the morning and afternoon sessions 1 day
following CFA injection as a control for possible CFA-
induced aversion to the morning chamber (data not
shown). No chamber preferences were observed in these
animals on test day, with times of 411.2 ± 99.7 s in the
morning saline paired chamber and 406.1 ± 100.9 s
spent in the afternoon saline paired chamber. These
data indicate that introducing the CFA-induced pain 20
hrs prior to the start of chamber pairing (conditioning
day) did not produce an aversion to the morning paired
chamber.
T h ep o s s i b l ep r e s e n c eo fC F A - i n d u c e do n g o i n gp a i n
and its time course was then determined using condi-
tioned place preference (CPP) to spinal clonidine. No
pre-conditioning chamber differences were observed any
of the treatment groups, therefore all pre-conditioning
data were pooled for graphical representation. (Figure
1c,). Following the habituation period on the third day,
one group of rats received i.paw CFA or saline (CFA
D1). Administration of spinal clonidine 1 day following
CFA injection produced robust chamber preference
(Figure 1c; *p < 0.05 vs. pre-conditioning). To determine
if ongoing pain persisted across 4 days, a separate group
of rats received i.paw CFA or saline 1 day prior to the 3
day habituation period (CFA D4). Administration of
spinal clonidine 4 days following CFA injection failed to
induce chamber preference (Figure 1c; *p < 0.05 vs. pre-
conditioning). Rats that received intraplantar saline
failed to show preference for the clonidine paired cham-
ber irrespective of whether saline was administered 24
hrs or 4 days prior to conditioning day (p > 0.05).
Therefore, all saline data were pooled for graphical
representation. Difference scores confirmed that CFA
treated rats demonstrated conditioned place preference
to the clonidine paired chamber 1 day, but not 4 days
following CFA injection (Figure 1d; *p < 0.05 vs. saline).
Spinal administration of clonidine attenuated CFA-
induced thermal hyperalgesia 1 day following CFA injec-
tion (Figure 1e,
#p<0 . 0 5v s .p r e - C F A ;* p<0 . 0 5v s .
post-CFA). Clonidine fully reversed CFA-induced ther-
mal hyperalgesia at the D4 time-point, and produced
antinociception, with paw-flick latencies significantly
higher than pre-CFA baseline values (Figure 1f,
#p<
0.05 vs. pre-CFA; *p < 0.05 vs. post-CFA) This dose
of spinal clonidine failed to alter paw-flick latencies of
control rats 1 or 4 days following intraplantar saline
(Figure 1e,f).
Ongoing pain is driven by peripheral input
Administration of lidocaine into the popliteal fossa 24
hrs following intraplantar CFA or saline produced a
nerve block as indicated by an essentially complete
blockade of responses to noxious thermal or mechanical
stimuli in saline and CFA-treated rats. Paw withdrawal
latencies to the noxious thermal stimulus were exten-
ded almost to cut-off following lidocaine injection
(Figure 2a,
#p < 0.05 vs. pre-CFA; *p < 0.05 vs. post-
CFA values). Similarly, administration of lidocaine into
the popliteal fossa raised paw withdrawal thresholds
evaluated with the Randall-Sellito test to near cut-off
levels in both CFA- and saline-pretreated rats (Figure
2b,
#p < 0.05 vs. saline; *p < 0.05 vs. post-CFA values).
This dose of lidocaine clearly impaired motor function
in both CFA and saline (control) treated rats determined
by visual inspection of locomotion. Motor function was
fully recovered in these rats within 2 hrs of lidocaine
injection.
To determine the role of injury-induced peripheral
drive ongoing pain, animals were treated with lidocaine
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Page 2 of 11Figure 1 A. Hindpaw CFA produced lower paw withdrawal latencies within 24 hours (D1). Paw withdrawal latencies remained lower than
pre-injury baseline (BL) 4 days following injury, but were higher than those observed 1 day following injury. *p < 0.05 vs. pre-injury thresholds
(BL);
#p < 0.05 vs. D1 thresholds, n = 7-8. B. Hindpaw CFA produced guarding behavior within 24 hours (D1). Guarding behavior remained
elevated compared to pre-injury baselines (BL) 4 days following injury, but was significantly reduced compared to the D1 time-point. *p < 0.05
vs. pre-injury thresholds (BL);
#p < 0.05 vs. D1 thresholds, n = 7-8. C. Spinal clonidine (10 μg) induced CPP selectively in CFA treated rats at day 1,
but not day 4 post CFA, injection. No chamber preference is observed in saline treated rats indicating that this dose of spinal clonidine is not
rewarding in the absence of injury. *p < 0.05 vs. saline paired chamber;
#p < 0.05 vs. pre-conditioning, n = 7. D. Difference scores calculated as
test time - preconditioning time spent in clonidine chamber confirm that CFA treated rats showed CPP 24 hrs, but not 4 days post CFA
injection. *p < 0.05 vs. saline treated group. E. CFA decreased paw withdrawal latencies to radiant heat within 24 hours of injection (Post-CFA).
Spinal clonidine (10 μg) attenuated, but did not fully reverse CFA-induced thermal hyperalgesia. This dose of spinal clonidine failed to induce
antinociception in rats that received intraplantar saline, *p < 0.05 vs. post-CFA,
#p < 0.05 vs. pre-CFA, n = 5-8. F. CFA-induced thermal
hyperalgesia persisted through day 4 post-CFA. Spinal clonidine (10 μg) induced antihyperalgesia and antinociception, elevating paw withdrawal
latencies above baseline values. *p < 0.05 vs. post-CFA,
#p < 0.05 vs. pre-CFA, n = 5-8.
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ing day, 24 hrs following intraplantar administration of
CFA or saline. No pre-conditioning chamber differences
were observed across any condition, therefore data were
pooled for graphical representation (Figure 2c). On test
day, 20-24 hrs following conditioning, animals were
tested for chamber preference in the absence of popli-
teal fossa lidocaine, eliminating potential effects of
motor impairment on chamber exploration. Rats treated
with CFA 24 hours prior to conditioning demonstrated
preference for the chambers paired with popliteal fossa
lidocaine. Rats that received CFA 4 days prior to condi-
tioning and the saline treated rats did not show prefer-
ence (Figure 2c, *p < 0.05 vs. pre-conditioning).
Comparison of difference from baseline scores confirm
that rats treated with CFA 24 hrs prior to conditioning
increased time spent in the lidocaine paired chambers
following conditioning whereas rats treated with CFA 4
days prior to conditioning did not (Figure 2d, *p < 0.05
vs. saline).
Figure 2 A. CFA reduced withdrawal latency within 24 hrs post-CFA. Popliteal fossa lidocaine (4% w/v, 200 μl) reversed CFA-induced
hypersensitivity, elevating paw withdrawal latencies to noxious thermal stimulation to almost cut-off in both CFA and control (saline) treated rats
at the 15 min time-point. Elevated paw-flick latencies were observed throughout the 60 min testing period in the CFA treated rats, and returned
to pre-lidocaine latencies within 45 min in the control rats, *p < 0.05 vs. post-CFA,
#p < 0.05 vs. pre-CFA, n = 5-6. B. CFA decreased withdrawal
thresholds to noxious mechanical stimulation within 24 hrs. Popliteal fossa lidocaine elevated paw-withdrawal thresholds to almost cut-off in
both the CFA and saline (control) groups at the 15 min time-point. Paw-withdrawal thresholds returned to pre-lidocaine values within 30 min for
control rats, and within 45 min in the CFA treated rats, *p < 0.05 vs. post-CFA,
#p < 0.05 vs. pre-CFA, n = 5-6. C. Popliteal fossa lidocaine induced
CPP 24 hrs, but not 4-days post-CFA injection. *p < 0.05 vs. pre-conditioning, p < 0.05, n = 5-6. D. Difference scores calculated as test time -
preconditioning time spent in lidocaine chamber confirm that only rats treated with CFA 24 hours prior to conditioning showed CPP in
response to peripheral nerve block by lidocaine. *p < 0.05 vs. saline treated group.
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TRPV1 positive fibers
Systemic administration of RTX has been demonstrated
to produce long-lasting desensitization of TRPV1-
expressing nociceptors [14] and to essentially eliminate
sensitivity to noxious thermal stimuli in animals [15].
Rats treated with RTX failed to respond to a noxious
thermal stimulation (Figure 3a, *p < 0.05 vs. pre-RTX).
Separate groups of rats were observed for guarding
behavior 24 hours following CFA. Systemic administra-
tion of RTX 3 days prior to injury blocked the injury-
induced guarding behavior (Figure 3b, *p < 0.05 vs.
vehicle). RTX administration prior to habituation
blocked CPP resulting from administration of lidocaine
into the popliteal fossa in CFA treated rats (Figure 3c,
*p < 0.05 vs. pre-conditioning). Rats treated with i.paw
saline (controls) did not show preference for the lido-
caine paired chamber irrespective of RTX treatment.
Difference from baseline values confirm that CFA trea-
ted rats that did not receive RTX (vehicle) showed
increased time in the lidocaine paired chambers whereas
CFA treated rats that received RTX treatment did not
show increased time spent in the lidocaine paired cham-
ber (Figure 3d, *p < 0.05 vs. vehicle).
Figure 3 A. RTX (0.1 mg/kg, i.p.) treatment 4 days prior to testing blocked thermal nociception with all responses on the hot plate
(52°C) reaching the cut-off time (32 s). CFA reduced the thermal response latency within 24 hr in animals that received vehicle for RTX.
Thermal hypersensitivity was completely blocked in the RTX treated group. *p < 0.05 vs. pre-RTX;
#p < 0.05 vs. vehicle, n = 7. B. RTX treatment 4
days prior to testing blocked CFA induced guarding of the hindpaw observed 24 hours following injury. *p < 0.05 vs. vehicle treated, n = 8-10.
C. RTX treatment 1 day prior to testing prior to habituation blocked CPP to chambers paired with lidocaine administration into the popliteal
fossa in CFA treated rats 24 hr post-CFA. Rats that received saline into the hindpaw failed to show preference for the lidocaine paired chamber
irrespective of RTX treatment. *p < 0.05 vs. pre-conditioning, n = 6-8. D. Difference scores calculated as test time - preconditioning time spent in
lidocaine chamber confirm that only CFA treated rats that did not receive RTX (Vehicle) showed preference for the lidocaine paired chamber.
*p < 0.05 vs. saline treated group.
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on TRPV1 receptors
In agreement with previous reports [16], systemic
administration of the TRPV1 receptor AMG9810 (30
mg/kg, i.p.) blocked CFA-induced thermal hypersensitiv-
ity 1 day post CFA injection (Figure 4a, *p < 0.05 vs.
post-CFA,
#p < 0.05 vs. pre-CFA).
To determine whether selective blockade of the
TRPV1 receptor blocks CFA-induced pain, rats received
systemic administration AMG9810 (30 mg/kg, i.p.) and
were observed for guarding behavior 24 hours following
injury. Administration of the TRPV1 antagonist failed to
block guarding behavior in CFA treated rats (Figure 4b).
To determine whether selective blockade of the
TRPV1 receptor blocks injury induced ongoing pain,
rats underwent single trial CPP to popliteal fossa
lidocaine in the presence of AMG9810 (30 mg/kg, i.p.)
or vehicle 24 hours following CFA administration. No
pre-conditioning chamber differences were observed
across any condition, therefore data were pooled for gra-
phical representation (Figure 4c). Rats received hindpaw
injection of saline or CFA immediately following base-
line assessment. On conditioning day, rats received sys-
temic administration of PEG400 (vehicle for AMG9810)
30 min before popliteal fossa administration of saline
and placed into a pre-determined pairing chamber. Four
hours later, rats received AMG9810 (30 mg/kg, i.p.) or
PEG400 30 min before popliteal fossa administration of
lidocaine and placed into the opposite pairing chamber.
Following conditioning, CFA treated rats showed CPP
to the lidocaine paired chamber irrespective of whether
they received AMG9810 (Figure 4c, *p < 0.05 vs.
Figure 4 A. CFA reduced withdrawal latency within 24 hrs post-CFA. AMG9810 (30 mg/kg, i.p.) reversed CFA-induced thermal hyperalgesia
within 15 min, with paw-flick latencies returning to pre-drug levels 60 min post administration. AMG9810 also elevated paw-flick latencies of
control (saline treated) rats with 15 min of administration. *p < 0.05 vs. post-CFA,
#p < 0.05 vs. pre-CFA, n = 5-6. B. Systemic administration of
the selective TRPV1 receptor antagonist, AMG9810 (30 mg/kg i.p.) failed to alter CFA-induced guarding behavior 24 hours following injury, p >
0.05 vs. vehicle. C. Pre-conditioning values did not differ between treatment groups, therefore values were pooled for graphical representation.
Lidocaine increased time spent in the lidocaine paired chambers in both the AMG9810 and vehicle treated rats, *p < 0.05 vs. pre-conditioning,
n = 5. D. Difference scores calculated as test time - preconditioning time spent in the lidocaine chamber confirm that CFA treated rats increased
time spent in the lidocaine paired chambers in both the vehicle and AMG9810 treatment groups, *p < 0.05 vs. saline/vehicle.
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that AMG9810 failed to block popliteal fossa lidocaine
induced CPP (Figure 4d, *p < 0.05 vs. saline-vehicle).
Discussion
The present study provides a direct demonstration that
hindpaw injury elicits transient injury-driven ongoing
pain that is temporally distinct from long-lasting evoked
hypersensitivity. The temporal dissociation between
injury-induced ongoing pain and evoked hypersensitivity
supports previous suggestions of mechanistic differences
in these components of inflammatory pain [12,13,17,18].
Additionally, the data indicate that ongoing pain
induced by inflammation injury (CFA) is dependent
upon input from TRPV1 positive afferent fibers, likely
driven from the injury. Our data indicate that CFA-
induced injury provides a tonic aversive stimulus that
persists for at least one day post-injury and that relief
from this aversive state is sufficient to induce reward,
consistent with negative reinforcement. Pain relief was
induced by spinal clonidine or peripheral nerve block,
manipulations at sites that do not directly activate the
reward pathway. These data are the first to demonstrate
reward in animals by peripheral nerve block following
injury.
Consistent with many previous reports, this study con-
firmed that CFA induced long-lasting hypersensitivity to
acute application of both noxious and non-noxious (tac-
tile) stimulation [7-9,19,20]. Whether, and when, such
injuries might elicit ongoing pain, however, was not
definitively known. Lawson and colleagues detected
time-dependent foot-lifting behaviors at day 1 following
CFA but this behavior was virtually absent by post-CFA
day 4 [6]. However, whether such behaviors reflect
ongoing pain has been questioned [12]. Treatment with
CFA produce clear evoked hypersensitivity at day 1,
which diminishes within 4 days, suggestive of more
intense “pain” at day 1 than at later time points. A high
degree of evoked hypersensitivity might contribute to
avoidance of contact with surfaces, resulting in foot-lift-
ing behaviors [12]. Previous studies have demonstrated
that CFA induces mechanical sensitization in both A-
and C-fibers as well as other indicators of neuronal sen-
sitization including spontaneous activity and expanded
receptive fields within 24 hrs of CFA injection [20].
Moreover, the study of Lawson and colleagues revealed
that CFA induced a significant (>25%) increase in per-
centages of C- and Aδ fibers that showed spontaneous
discharge both at day 1 and day 4 post-CFA, in spite of
differences in foot-lifting behaviors at these points [6].
Work by Xiao and Bennett has demonstrated that CFA
treatment induces spontaneous discharge of C-fibers
that are similar across days 2-7 post-treatment and that
additionally, both the frequency and prevalence of such
spontaneous afferent activity is very low making it
uncertain whether this level of afferent drive might elicit
ongoing pain [10].
In the present studies, we demonstrated CPP following
spinal clonidine or lidocaine injection into the popliteal
fossa (local nerve block) at 24 hrs, but not 4 days fol-
lowing injection, suggesting the transient presence of
ongoing pain in this model. Spinal clonidine did not
induce CPP in non-CFA treated rats indicating that this
dose of spinal clonidine did not elicit reward in the
absence of pain. The lack of clonidine- or peripheral
lidocaine- induced CPP at post-CFA day 4 suggests that
injury induced ongoing pain is either absent, or greatly
diminished, so that any possible pain relief elicits insuffi-
cient negative reinforcement that is detectable in the
CPP paradigm. A previous study has explored whether
CFA-induced inflammation may represent an aversive
stimulus that might be detectable with CPP following
administration of drugs for pain relief [18]. In that
study, however, a clear demonstration of negative rein-
forcement was not achieved, likely due to differences in
route and timing of administration of pain relieving
drugs and other differences in experimental conditions.
The conclusion of transient ongoing pain with CFA-
induced inflammation is consistent with clinical knowl-
edge indicating that pain is maximal immediately follow-
ing injury and diminishes with time. Injuries associated
with peripheral inflammation (e.g., surgery) elicit initial
transient “spontaneous” pain (driven by the injury) fol-
lowed by much longer lasting evoked hypersensitivity
(i.e., tenderness) of the injured area [21-25]. The charac-
teristics of CFA-induced pain have been documented in
a human report [26]. In this report, the consequences of
accidental CFA injection into the third digit of the left
hand elicited spontaneous “throbbing” pain across the
first 24-30 hrs that had diminished within 48 hrs and
that was extinct by 7 days [26]. In spite of the dissipa-
tion of throbbing pain, evoked hypersensitivity persisted
for many weeks [26].
Studies by Brennan and colleagues have used a plantar
incision model to demonstrate the presence of time-
dependent guarding behaviors following plantar incision
that involves skin, fascia and underlying muscle [13].
Guarding behaviors were more modest in the absence of
incision of muscle tissue suggesting a strong contribution
of nociceptive afferents from this tissue in driving
ongoing pain. Increased spontaneous activity of muscle
nociceptors was observed one day after skin and deep tis-
sue injury that returned to control levels by 7 days post-
incision, corresponding to measures of guarding beha-
viors [13]. These studies suggested a requirement for
afferent drive from deep tissue in the generation of
ongoing pain following incision injury. This conclu-
sion appears consistent with the current behavioral
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Subcutaneous CFA produces an immune response in the
connective tissue sheath that covers the muscle as well as
within the muscle itself and this may therefore elicit
spontaneous discharge and sensitization of muscle affer-
ents [10]. In our studies, peripheral nerve block with infil-
tration of lidocaine within the popliteal fossa was
demonstrated to produce CPP only in rats with hindpaw
inflammation on post-injury day 1. The demonstration of
reward following pain relief by peripheral nerve block
indicates that afferent drive, likely from deep muscle
nociceptors, provides a significant and ongoing aversive
stimulus. This aversive stimulus likely mimics the transi-
ent features of the inflammatory state associated with
trauma, e.g., such as post-operative pain.
Nerve block by local anesthetic injection upstream of
tissue injury replicates routine clinical practice to pro-
duce relief of pain [27]. It is important to note that CPP
was observed following popliteal fossa lidocaine only in
injured rats, supporting the conclusion that CFA pain is
aversive, driven by primary afferent fibers, and that relief
of such pain by nerve block is sufficient to elicit reward.
Administration of lidocaine into the popliteal fossa was
confirmed to produce an effective nerve block as
demonstrated by thermal and mechanical response
thresholds that were raised to near cut-off levels in both
CFA and saline-treated rats. Demonstration of CPP by a
peripheral manipulation such as nerve block has not
previously been reported but this result would be pre-
dicted if there was negative reinforcement arising from
relief of an ongoing aversive stimulus, in this case result-
ing from injury-induced increased in input from noci-
ceptive afferent fibers.
The TRPV1 receptor is a signal transduction channel
primarily located on small to medium diameter primary
afferent fibers that responds to noxious thermal stimula-
tion and to acidic environments [28]. This receptor has
been demonstrated to play an important role in inflam-
mation injury induced evoked pain [16,29]. Here, we
produced prolonged desensitization of TRPV1 positive
fibers using resiniferatoxin (RTX) [30]. Systemic admin-
istration of RTX has been demonstrated to induce long-
lasting insensitivity to thermal stimulation while leaving
nociceptive mechanical thresholds unaltered [15,30].
Pretreatment with RTX eliminated responses to noxious
thermal stimuli in CFA-treated rats consistent with pre-
vious observations in other injury models [19].
In the present studies, CFA-induced ongoing pain was
abolished by desensitization of TRPV1 positive afferent
fibers following pretreatment with RTX. This result sug-
gests that this subpopulation of nociceptive afferents is
r e s p o n s i b l ef o rt h ea v e r s i v en a t u r eo fo n g o i n gp a i nf o l -
lowing hindpaw inflammation. This conclusion is
consistent with data from studies of incisional pain.
Brennan and colleagues have shown that local infiltra-
tion, or perineural administration of capsaicin decreased
guarding behaviors as well as afferent spontaneous activ-
ity supporting a requirement for TRPV1 positive fibers
in ongoing pain resulting from plantar incision [31,32].
Consistent with these findings, RTX treatment blocked
CFA-induced guarding behavior in rats. In contrast,
selective blockade of the TRPV1 receptor with an
antagonist failed to block guarding behavior induced by
CFA. This is consistent with other reports demonstrat-
ing that selective blockade of the TRPV1 receptor at a
dose sufficient to block thermal hypersensitivity failed to
block incision-induced guarding behavior [33]. Our stu-
dies are consistent with these conclusions in that block-
ade of the TRPV1 channel failed to block ongoing pain.
Here, CPP was elicited by peripheral nerve block regard-
less of blockade of the TRPV1 receptor. Thus, manipu-
lations that selectively block function of TRPV1 positive
fibers are sufficient to block ongoing pain, guarding
behavior, and thermal hypersensitivity whereas selective
blockade of the TRPV1 channel alone is insufficient to
block injury-induced ongoing pain. These data suggest
that other, non-TRPV1 targets on TRPV1 positive fibers
are mediating injury-induced ongoing pain.
Conclusions
The current study demonstrates that injury induces a
transient state of ongoing pain that is temporally and
mechanistically distinct from evoked hypersensitivity.
Detailed investigation of mechanisms driving ongoing
versus evoked pain may prove essential in development
of effective drugs targeting different aspects of clinically
relevant pain. CFA induced ongoing pain is driven by
afferent input, specifically TRPV1 positive nociceptive
fibers. Thus, targeted disruption of injury-induced med-
iators driving this class of afferent fibers may prove
important in providing effective pain relief for patients
with ongoing acute pain associated with injury accompa-
nied by inflammation as epitomized by pain at rest in
early post-surgical periods. Such therapies would lack
central effects associated with opioids, currently the
most commonly used post-operative therapy.
Materials and methods
Animals
Male Sprague-Dawley rats (Harlan, Indianapolis, IN)
weighing 250-275 g were used in all studies. All proce-
dures involving animals were reviewed and approved by
the Institutional Animal Care and Use Committee of
the University of Arizona, and were in accord with the
guidelines established by the National Institutes of
Health.
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Rats were anesthetized with isofluorane and intrathecal
catheters were implanted as previously detailed [34]. The
atlanto-occipital membrane was exposed, an incision was
made in the dura mater, and PE-10 tubing was advanced
8 cm caudally to the lumbar spinal cord. The tubing was
exteriorized, filled with saline and plugged with wire. The
wound was closed, and animals allowed to recover for 7
days. Notably, baseline testing prior to the 7 day recovery
period results in limited chamber crossings and resultant
chamber bias in the place preference apparatus, likely
due to the invasiveness of the surgery.
Induction of injury
Rats received intraplantar injection of complete Freund’s
adjuvant (CFA) (100 μl, s.c.; Calbiochem) into the left hind-
paw.Control rats received an equivolume saline injection.
Drug administration
Spinal administration
Clonidine (10 μg; Tocris Bioscience) or saline (vehicle
control) was delivered through an intrathecal catheter in
a5μl volume followed by a 9 μl saline flush. Progress
was monitored with an air bubble.
Popliteal fossa administration
Lidocaine (4% w/v; Roxane Laboratories) or saline (vehi-
cle control) was delivered in a 200 μl volume. Pilot stu-
dies with dye injections confirmed that this volume
successfully covered sciatic nerve and included the
branches of the sciatic nerve at the bifurcation including
the common peroneal, sural, and tibial nerves located
within the popliteal fossa [35].
Systemic drug administration
The ultrapotent TRPV1 receptor agonist, resiniferatoxin
(RTX, Tocris Bioscience), was dissolved in 99.1% saline,
0.3% Tween 80, and 0.6% Ethanol (used as a vehicle
control). RTX was administered systemically (0.1 mg/kg,
i.p.) in a dose previously demonstrated to eliminate
thermal responses across a period of 40 days, the long-
est time-point tested [15]. RTX was delivered 4 days
prior to testing of evoked pain or 1 day prior to habitua-
tion for the CPP procedure, a time corresponding to 4
days prior to conditioning day. The TRPV1 receptor
antagonist, AMG9810, was dissolved in PEG400 (used
as the vehicle control). AMG9810 was administered sys-
temically at a dose (30 mg/kg, i.p.) previously demon-
strated to effectively block CFA-induced thermal and
tactile hypersensitivity [16].
Behavioral observations
Thermal antinociception and hypersensitivity
Nociceptive withdrawal thresholds to noxious radiant
heat were determined using the plantar test apparatus
(Ugo Basile, Comerio, Italy) as previously described [15].
A maximal cut-off time of 32 s was used to prevent tis-
sue damage. Elimination of thermal responsiveness in
rats treated with RTX was determined with a hotplate
(Columbus Instruments) set at 52°C. Latency to the first
escape response (jumping, licking, or climbing) was
recorded.
Mechanical hypersensitivity
Withdrawal thresholds to noxious mechanical stimula-
tion were determined using a Randall-Selitto apparatus
(Ugo Basile, Comerio, Italy). A positive response was
indicated by withdrawal of the paw. A cut-off of 400 g
was used to avoid tissue injury.
Tactile hypersensitivity
Paw withdrawal thresholds were determined in response
to probing with calibrated von Frey filaments (Stoelting,
Wood Dale, IL) using the “up and down” method and
analyzed using a Dixon nonparametric test [36,37].
Guarding behavior
Assessment of guarding behavior was done across a 30
min period in which each rat was observed for 10 sec at
1 min intervals. Rats were observed and scored accord-
ing to a scale as previously described [13,38], in which 0
was scored when the CFA treated hindpaw area was
touching the mesh, and the area was blanched or dis-
torted by the mesh; 1 was scored when the CFA treated
hindpaw touched the mesh without blanching or distor-
tion; 2 for the position when the CFA treated hindpaw
was completely off of the mesh. For each hind paw, a
cumulative score was obtained by adding the 30 scores
during the 30 min testing period.
CPP Procedures
A single trial conditioning protocol was used for CPP
as previously described [1]. All rats underwent a 3 day
pre-conditioning habituation period with behavior
recorded on day 3 to verify no pre-conditioning cham-
ber preference. Analyses of the pre-conditioning (base-
line) time spent in the conditioning chambers showed
that rats spent equivalent time in the striped vs. the
black walled chambers indicating no pre-existing
chamber preference prior to counterbalancing further
suggesting that any post-conditioning preferences
observed reflect preference due to relief of ongoing
pain, and not other potential factors such as anxiolytic
effects of drug administration. On conditioning day,
rats received the appropriate vehicle control paired
with a chamber in the morning, and the appropriate
drug treatment paired with the other chamber 4 hr
later. Chamber pairings were counterbalanced. On test
day, 20 hrs following the afternoon pairing, rats were
placed in the CPP box with access to all chambers and
behavior was recorded for 15 min for analysis for
chamber preference.
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Effects of drug treatments on evoked pain were deter-
mined by 2-factor ANOVA for repeated measures with
time serving as a within-subject factor. Differences from
the post-treatment values were determined by Student-
Neuman-Keuls post-hoc test. CPP data were analyzed
before conditioning (baseline) and after conditioning
using two-factor ANOVA (chambers vs. treatment) fol-
lowed by Student’s t-test with Bonferroni correction. No
preconditioning differences in time spent in chambers
between saline and CFA treated rats were observed,
therefore baseline chamber data for each experiment
was pooled across treatment. For all analyses, signifi-
cance was set at p < 0.05.
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